Tumor Size Determines Treatment Modality in Uveal Melanoma
The treatment modality for uveal melanoma depends on the tumor’s thickness: brachytherapy alone for tumors <1 mm, brachytherapy with vitrectomy and silicone oil for tumors ≥2 mm, and enucleation for larger lesions.
A mix of treatment modalities was assessed in a recent study that looked at patients with uveal melanoma. Of the 37 patients enrolled in the trial, patients were treated with either brachytherapy alone (19%), brachytherapy plaque with vitrectomy and silicone oil for radiation attenuation (73%), or enucleation (8%).
Selecting the appropriate therapy based on tumor size can preserve vision, reduce surgical morbidity, and may influence the risk of metastatic spread.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies